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Abstract
Matrix metalloproteinase-9 (MMP-9) may play an im-
portant role in emphysematous change in chronic ob-
structive pulmonary disease (COPD), one of the lead-
ing causes of mortality and morbidity worldwide. We 
previously reported that simvastatin, an inhibitor of 
HMG-CoA reductase, attenuates emphysematous 
change and MMP-9 induction in the lungs of rats ex-
posed to cigarette smoke. However, it remained un-
certain how cigarette smoke induced MMP-9 and how 
simvastatin inhibited cigarette smoke-induced MMP-9 
expression in alveolar macrophages (AMs), a major 
source of MMP-9 in the lungs of COPD patients. 
Presently, we examined the related signaling for 
MMP-9 induction and the inhibitory mechanism of sim-
vastatin on MMP-9 induction in AMs exposed to ciga-
rette smoke extract (CSE). In isolated rat AMs, CSE in-
duced MMP-9 expression and phosphorylation of ERK 
and Akt. A chemical inhibitor of MEK1/2 or PI3K re-
duced phosphorylation of ERK or Akt, respectively, 
and also inhibited CSE-mediated MMP-9 induction. 
Simvastatin reduced CSE-mediated MMP-9 induction, 
and simvastatin-mediated inhibition was reversed by 
farnesyl pyrophosphate (FPP) or geranylgeranyl py-
rophosphate (GGPP). Similar to simvastatin, inhibition 
of FPP transferase or GGPP transferase suppressed 
CSE-mediated MMP-9 induction. Simvastatin attenu-
ated CSE-mediated activation of RAS and phosphor-
ylation of ERK, Akt, p65, IκB, and nuclear AP-1 or NF-κB 
activity. Taken together, these results suggest that 
simvastatin may inhibit CSE-mediated MMP-9 in-
duction, primarily by blocking prenylation of RAS in the 
signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, 
AP-1, and IκB-NF-κB are involved.
Keywords: macrophages, alveolar; matrix metal-
loproteinases-9; pulmonary disease, chronic obstruc-
tive; pulmonary emphysema; simvastatin; smoking
Introduction
Chronic obstructive pulmonary disease (COPD) is 
characterized by progressive and irreversible air-
flow limitation, which is usually associated with an 
abnormal inflammatory response to noxious parti-
cles or gases, mainly cigarette smoke (Rabe et al., 
2007). According to the World Health Organization, 
(COPD) will emerge as the third leading cause of 
death and rank fifth in 2020 in burden of disease 
worldwide by 2020 (Rabe et al., 2007). COPD 
manifests with two pathological features, emphy-
sema and chronic bronchitis. Emphysema is cau-
sed by destruction of walls of the distal airways 
and alveolar sacs, leading to enlargement of airs-
paces.
    Cigarette smoke harbors a multitude of chemical 
compounds and causes direct oxidative lung da-
mage and indirect damage through the activation 
of various lung cells including alveolar macro-
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Figure 1. Induction of MMP-9 in AMs by CSE in time-dependent (A) and concentration-dependent (B) manners. (A) After exposing AMs to 2.5% CSE, 
conditioned media and AMs were harvested at indicated time points for gelatin zymography and RT-PCR of MMP-9 mRNA, respectively. (B) Forty-eight 
hours after exposure to different concentrations of CSE, gelatin zymography and RT-PCR of MMP-9 were performed. Expression of MMP-9 mRNA was 
normalized with expression of GAPDH mRNA. * or ** indicates statistical difference (P ＜ 0.05) in comparison with levels at 0 h or 0% CSE, respectively.
phages (AMs) (Barnes et al., 2003). Activated AMs 
are suggested to amplify the inflammatory res-
ponse through the liberation of various chemokines/ 
cytokines required for recruitment and activation of 
other inflammatory cells such as neutrophils. The 
number of AMs is elevated in sputum, bronchoal-
veolar lavage fluid, airways, and lung parenchyma 
of smokers and patients with COPD (Barnes, 
2004). The numbers of AMs in the alveolar walls 
correlates to the severity of COPD (Di Stefano et 
al., 1998). Moreover, AMs are localized to the sites 
of alveolar wall destruction in patients with emphy-
sema (Finkelstein et al., 1995; Meshi et al., 2002). 
AMs activated by cigarette smoke extract (CSE) 
release inflammatory mediators such as TNF-α 
(Churg et al., 2003) and IL-8 (Culpitt et al., 2003) to 
provoke inflammation in the lungs of the individual 
smoker.
    In addition, AMs also secrete several elastolytic 
enzymes including matrix metalloproteinase (MMP)- 
2, MMP-9, and MMP-12; cathepsins K, L, and S; 
and neutrophil elastase taken up from neutrophils 
(Punturieri et al., 2000; Russell et al., 2002). 
Among the proteases liberated from AMs, MMP-9 
has been suggested to play an important role in 
development of emphysema in COPD. In patients 
with emphysema, expression of MMP-9 is elevated 
in AMs (Betsuyaku et al., 1999), and AMs from 
normal smokers express more MMP-9 than those 
from normal subjects (Lim et al., 2000). Moreover, 
AMs from patients with COPD display elevated 
basal- and CSE-induced MMP-9 activities (Russell 
et al., 2002).
    Previously (Lee et al., 2005), we demonstrated 
that simvastatin, an inhibitor of HMG-CoA reduc-
tase, can successfully attenuate emphysematous 
changes and reduce the increase in MMP-9 acti-
vities in the lung tissues of rats exposed to ciga-
rette smoke for 16 weeks. Beyond a lipid lowering 
effect by inhibiting HMG-CoA, statins have other 
pleiotropic effects that include improving or resto-
ring endothelial function, inhibiting the proliferation 
and migration of smooth muscle cells, decreasing 
vascular inflammation, and enhancing stability of 
atherosclerotic plaques (Liao and Laufs, 2005). 
Furthermore, statins suppress MMP-9 expression 
in macrophages in atheromatous lesions (Aickawa 
et al., 2001), vascular smooth muscle cells (Turner 
et al., 2005), and cancer cells (Denoyelle et al., 
2001).
    While simvastatin alleviated emphysematous 
changes possibly through inhibiting MMP-9 induc-
tion in the lung tissues of rats exposed to cigarette 
smoke in our previous study, it remains unknown 
whether simvastatin inhibits CSE-mediated MMP-9 
induction in AMs which are believed to orchestrate 
inflammatory and destructive responses to ciga-
rette smoking (Barnes, 2004). Furthermore, it is 
unclear how cigarette smoke mediates MMP-9 
induction in AMs. Presently, we sought to deter-
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Figure 2. Involvement of MEK-ERK or PI3K-Akt in CSE-mediated MMP-9 induction in AMs. (A) Inhibition of CSE-mediated MMP-9 induction by chemical 
inhibitors. Chemical inhibitors were given 1 h prior to CSE administration to suppress MEK [10 μM PD98059 (PD), or 1 μM U0126 (U)], p38 MAPK (10 
μM SB203580), JNK [10 μM SP600125 (SP)], or PI3K (10 μM LY294002). Forty-eight hours after exposure to 2.5% CSE, gelatin zymography and 
RT-PCR of MMP-9 were performed. * or ** indicates statistical difference (P ＜ 0.05) in control vs. CSE-exposed group, or CSE-exposed vs. in-
hibitor-treated groups, respectively. (B) Phosphorylation of ERK and Akt by CSE in AMs. After CSE exposure, AMs were harvested at the indicated times, 
and phosphorylation of ERK and Akt was determined by Western blot. Levels of phosphorylated ERK or Akt were normalized with total ERK or Akt, 
respectively. * indicates statistical difference (P ＜ 0.05) in comparison with the levels at 0 h.
mine the related signaling for MMP-9 induction and 
the inhibitory mechanism of simvastatin on MMP-9 
induction in rat AMs exposed to CSE.
Results
CSE increases MMP-9 secretion and MMP-9 mRNA 
expression in rat AMs
MMP-9 induction by CSE exposure was investiga-
ted in isolated AMs. After exposure of AMs to 2.5% 
CSE, the MMP-9 activities in the conditioned me-
dium and the expression of MMP-9 mRNA were 
determined at various times by gelatin zymography 
and RT-PCR, respectively (Figure 1A). Significant 
increase in the expression of MMP-9 mRNA was 
observed 24 h and 48 h after CSE treatment, with 
maximum induction at 48 h. In accordance with the 
changed expression of MMP-9 mRNA, gelatinolytic 
activities around 92 kDa increased in a similar 
manner. However, the 82 kDa active form of 
MMP-9 was not evident in gelatin zymograms. This 
absence of active MMP-9 implies the deficiency of 
extracellular proteolytic cleavage of secreted pro- 
MMP-9 under the experimental conditions.
    Next, varying concentrations of CSE were added 
to AMs, and gelatin zymography and RT-PCR 
detection of MMP-9 were done 48 h later (Figure 
1B). CSE induced both MMP-9 activity and mRNA 
expression in a concentration-dependent manner, 
whereas 5% CSE suppressed MMP-9 induction. 
Since higher concentrations of CSE might cause 
cytotoxicity (Aoshiba et al., 2001) or nonspecific 
suppression of cellular function, we subsequently 
used 2.5% CSE to maximally induce MMP-9.
MEK-ERK and PI3K-Akt are involved in 
CSE-mediated induction of MMP-9
MAPK and PI3K/Akt are known to be involved in 
MMP-9 induction in different types of cells stimu-
lated by different stimuli (Gum et al., 1997; Lai et 
al., 2003; Lu and Wahl, 2005; Cheng et al., 2006; 
Han et al., 2006). Therefore, to identify the signa-
ling pathways related to CSE-mediated MMP-9 
induction, AMs were pretreated with inhibitors of 
each signaling molecule 1 h before CSE exposure, 
with MMP-9 secretion and MMP-9 mRNA expre-
ssion being determined 48 h later. Both 10 μM 
PD98050 and 1 μM U0126, which are both MEK1/2 
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Figure 3. Absence of cross talk between MEK-ERK and PI3K-Akt 
pathways. MEK inhibitors [(10 μM PD98059 (PD) or 1 μM U0126 (U)] or 
a PI3K inhibitor (10 μM LY294002) were given 1 h prior to CSE 
exposure. Five min after CSE exposure, AMs were harvested and phos-
phorylation of ERK and Akt was determined by Western blot.
Figure 4. Inhibition of CSE-mediated MMP-9 induction by simvastatin in 
AMs. AMs were pretreated with vehicle (DMSO) or simvastatin (SIM) at 
the indicated concentrations 1 h prior to addition of 2.5% CSE. After 48 h, 
conditioned media and AMs were examined by gelatin zymography and 
MMP-9 RT-PCR, respectively. * or ** indicates statistical difference (P ＜
0.05) in comparison with the control or CSE-exposed group, respectively.
inhibitors, effectively abrogated CSE-induced in-
crease in MMP-9 secretion and MMP-9 mRNA ex-
pression (Figure 2A). Similarly, 10 μM of the PI3K 
inhibitor LY294002 decreased MMP-9 induction. 
However, neither SB203580 (a p38 MAPK inhi-
bitor) or SP600125 (a JNK inhibitor) displayed inhi-
bitory effect on CSE-mediated MMP-9 induction.
    As ERK1/2 are downstream to MEK1/2, and Akt 
downstream to PI3K is involved in MMP-9 expre-
ssion (Chung et al., 2004; Lu and Wahl, 2005; 
Cheng et al., 2006), phosphorylation status of ERK 
or Akt was checked by Western blot to confirm the 
involvement of MEK-ERK or PI3K-Akt in CSE-me-
diated MMP-9 induction. Phosphorylation of ERK1/2 
was increased 5 min after CSE exposure, and 
gradually returned to basal level (Figure 2A). Phos-
phorylation of ERK1/2 significantly increased again 
at 24 h. Similarly, phosphorylation of Akt was in-
creased by CSE at 5 min. However, dissimilar to 
ERK, there was no late phosphorylation of Akt at 
24 h. Similar to the effects on MMP-9 induction, the 
MEK and PI3K inhibitors successfully inhibited 
phosphorylation of ERK1/2 and Akt, respectively 
(Figure 3). However, MEK inhibitors did not affect 
phosphorylation of Akt and the PI3K inhibitor did 
not decrease phosphorylation of ERK1/2. These 
observations suggest the involvement of MEK- 
ERK1/2 and PI3K-Akt in CSE-mediated MMP-9 
induction in AMs in a process that does not involve 
pathway cross-talk.
Simvastatin inhibits MMP-9 induction in rat AMs 
exposed to CSE
As we observed attenuation of MMP-9 induction in 
a rat model of cigarette smoke-induced emphy-
sema, we determined whether simvastatin might 
inhibit CSE-mediated MMP-9 induction in AMs. 
Simvastatin successfully reduced both MMP-9 se-
cretion and MMP-9 mRNA expression in a concen-
tration-dependent manner, with maximum inhibition 
at 10 μM simvastatin (Figure 4).
Simvastatin inhibits MMP-9 induction through 
protein prenylation
In addition to their inhibitory action on cholesterol 
synthesis, the pleiotropic effects of statins are 
partly explained by inhibition of synthesis of me-
vaolonate, a precursor of isoprenoids including FPP 
and GGPP, which are required for prenylation of 
small GTPase including RAS and Rho proteins 
(Jain and Ridker, 2005; Liao and Laufs, 2005). 
Moreover, RAS (Moon et al., 2004; Lee et al., 
2006) and Rho proteins (Turner et al., 2005) are 
related to MMP-9 expression. Accordingly, we 
investigated whether simvastatin could suppress 
CSE-mediated MMP-9 induction via the inhibition 
of protein prenylation. Supplementation of FPP or 
GGPP before CSE exposure restored CSE-media-
ted MMP-9 induction (MMP-9 secretion and MMP-9 
mRNA expression) in AMs treated with simvastatin 
(Figure 5). Conversely, 10 μM of either FTI-277 (a 
farnesyl transferase inhibitor) or GGTI-2133 (a 
geranylgeranyl transferase inhibitor) suppressed 
CSE-mediated MMP-9 induction similar to simvas-
tatin. In accordance with the inhibitory action on 
MMP-9 induction, simvastatin, FTI, or GGTI redu-
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Figure 6. Protein prenylation mediates activation of ERK and Akt by 
CSE in alveolar macrophages. Simvastatin was added 1 h before CSE 
exposure, and GGTI-2133 or FTI-277 was added 4 h before CSE 
exposure. Five min after CSE exposure, phosphorylation of ERK and Akt 
were determined by Western blot. * or ** indicates statistical difference (P
＜ 0.05) in comparison with the control or CSE-exposed group, 
respectively.
Figure 5. Simvastatin reduces MMP-9 induction through inhibition of iso-
prenoid synthesis. Isoprenoids (100 μM GGPP or 100 μM FPP) were 
added to AMs 1 h prior to administration of 10 μM simvastatin. CSE was 
added to AMs at a final concentration of 2.5%. A GGPP transferase in-
hibitor (GGTI-2133) or a FPP transferase inhibitor (FTI-277) was added 
at a final concentration of 10 μM 4 h before CSE exposure. After 48 h, 
MMP-9 secretion and MMP-9 mRNA expression were determined. *, +, 
or ** denotes statistical difference (P ＜ 0.05) in comparison with the 
control, simvastatin-treated, or CSE-exposed group, respectively.
ced phosphorylation of ERK and Akt in AMs 
exposed to CSE similar to simvastatin (Figure 6).
    Next, we determined the activation status of RAS, 
since lovastatin inhibits MMP-9 expression via the 
inhibited prenylation of RAS in vHRAS-transformed 
NIH 3T3 cells (Wang et al., 2000), and, as found 
presently, simvastatin, FTI or GGTI reduced CSE- 
mediated MMP-9 induction. CSE activated RAS in 
AMs, whereas simvastatin suppressed CSE-me-
diated RAS activation (Figure 7A). However, Rho 
activation was not detected, and neither cell-per-
meable C3 exoenzyme (a Rho inhibitor) nor Y- 
7632 (a ROCK inhibitor) inhibited MMP-9 induction 
(data not shown), which suggests no involvement 
of Rho-ROCK pathway in CSE-mediated MMP-9 
induction.
    Since the RAS-Raf-MEK-ERK pathway is activa-
ted by various stimuli, the involvement of Raf in 
CSE-mediated MMP-9 induction was investigated 
by the application of the specific Raf inhibitor GW 
5074. GW 5074 successfully inhibited CSE-media-
ted MMP-9 induction (Figure 7B). These data 
suggest that CSE induces MMP-9 expression 
through the activation of RAS, and that simvastatin 
inhibits MMP-9 induction possibly by inhibiting pre-
nylation of RAS, which subsequently transmits the 
signal to Raf.
Effect of simvastatin on downstream signaling 
molecules involved in MMP-9 expression
As AP-1 and NF-κB binding sites reside in the 
MMP-9 promoter region (Kim et al., 2007), and 
IKK-IκBα-p65 and AP-1 are involved in MMP-9 
expression (Eberhardt et al., 2000, 2002; Takada 
et al., 2005), we checked the inhibition of these 
downstream signaling by simvastatin. The IKK 
inhibitors BMS-335541 and IKK inhibitor VII su-
ppressed CSE-mediated MMP-9 induction (Figure 
8A), consistent with the involvement of IKK in 
MMP-9 induction. Simvastatin also inhibited phos-
phorylation of IκBα and p65, which were increased 
by CSE exposure (Figure 8B). In addition, simvas-
tatin inhibited the binding activities of NFκB and 
AP-1 in a gel shift assay (Figure 8C).
Discussion
In this study, we have demonstrated that CSE 
induces MMP-9 with activation of RAS, ERK, and 
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Figure 7. Involvement of RAS-Raf in CSE-mediated MMP-9 induction in AMs. (A) Inhibition of CSE-induced RAS activation by simvastatin. Three million 
rat AMs were seeded in a 35 mm-diameter dish. Simvastatin at 10 μM was added 1 h before addition of 2.5% CSE. Five min later, AMs were harvested 
and a RAS activation assay was performed. * or ** indicates statistical difference (P ＜ 0.05) in comparison with control or CSE-exposed group, 
respectively. (B) Involvement of Raf in CSE-mediated MMP-9 induction. The selective Raf inhibitor GW 5074 (10 μM) was added 1 h prior to CSE 
exposure. After 48 h, AMs were taken for MMP-9 RT-PCR.
Akt together with increased binding activities of 
AP-1 and NF-κB in AMs. The data obtained from 
chemical inhibitor experiments suggests the invol-
vement of Raf-MEK, PI3K, or IKK in the activation 
of these signaling molecules. Simvastatin success-
fully inhibited CSE-mediated MMP-9 induction by 
blocking isoprenoid synthesis, which is required for 
prenylation and activation of small GTPases, mainly 
RAS in this study. Simvastatin also reduced activa-
tion of ERK, Akt, AP-1, and NF-κB. These data 
support the suggestion that simvastatin may 
reduce CSE-mediated MMP-9 induction by inhibi-
ting the activation of RAS, subsequently Raf-MEK- 
ERK or PI3K-Akt, and, finally, AP-1 and NF-κB.
    Three RAS genes are translated into four RAS 
proteins: HRAS, NRAS, KRAS4A, and KRAS4B 
(KRAS4A and KRAS 4B are splice variants of a 
single gene). RAS proteins contain a CAAX motif 
(C, cysteine; A any aliphatic amino acids; X, any 
amino acid), which serves as a substrate for a 
series of post-translational modifications (Konstan-
tinopoulos et al., 2007). These modifications include 
the covalent attachment of FPP or GGPP to the 
cysteine residue of the CAAX motif by prenylation. 
HRAS is only farnesylated, whereas NRAS, 
KRAS4A, and KRAS4B can be farnesylated and 
geranylgeranylated. In this study, the inhibitory 
action of simvastatin was reversed by either FPP 
or GGPP, and FTI or GGTI mimicked the inhibitory 
action of simvastatin. Even though we did not 
identify the form of RAS, it seems unlikely that 
HRAS is the only RAS protein capable of inducing 
MMP-9 expression, because HRAS is only farne-
sylated, and either GGTI or FTI inhibited CSE- 
mediated MMP-9 induction in this experiment. Also, 
cross-prenylation may not be operative in RAS 
activation in CSE-mediated MMP-9 induction. 
Whereas FTIs prevents HRAS farnesylation and 
reverse HRAS-induced transformation (Kohl et al., 
1993), KRAS and NRAS can be geranylgerany-
lated (cross-prenylation) in FTI-treated cells, resul-
ting in persistent membrane association of KRAS 
and NRAS, and persistent downstream activation 
of MAPK/ERK (Whyte et al., 1997; Law et al., 2000). 
However, presently, single treatment of GGTI or 
FTI inhibited MMP-9 induction. So, the contribution 
of each form of RAS in CSE-mediated MMP-9 
induction remains unclear.
    RAS proteins activate Raf/MEK/ERK and PI3K/Akt 
pathways. In human primary monocytes, LPS sti-
mulation results in MMP-9 induction through a PI3K- 
Akt-IKK-NFκB pathway, in which p65 is activated 
(Lu and Wahl, 2005), while ERK mediates TNF-α- 
induced MMP-9 expression in human vascular 
smooth muscle cells via activation of NF-κB and 
AP-1 (Moon et al., 2004). In contrast, both MEK- 
ERK and PI3K-Akt pathways are suggested to 
activate both AP-1 and NF-κB in HBV X protein- 
transfected cells (Chung et al., 2004). Interestingly, 
ERK activity is increased not only in AMs of the 
mice chronically exposed to cigarette smoke but 
also in AMs of emphysema patients (Mercer et al., 
2004). However, it is not clear whether ERK 
activation may be caused directly by exposure to 
cigarette smoke or indirectly by pro-inflammatory 
chemokines/cytokines from activated AMs (Yang et 
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Figure 8. Effect of simvastatin on downstream signaling molecules involved in MMP-9 expression. (A) Involvement of IKK in CSE-mediated MMP-9 
induction. IKK inhibitors (10 μM BMS-345541 (BMS) or 1 μM IKK VII inhibitor (IKK-i)) were added to rat AMs 1 h prior to exposure to 2.5% CSE. After 48 
h, MMP-9 mRNA expression was determined. * or ** indicates statistical difference in comparison with control group, or CSE-treated group, respectively. 
(B) Inhibition of CSE-mediated phosphorylation of IκBα and p65 by simvastatin. Simvastatin at 10 μM was added 1 h prior to addition of 2.5% CSE. 24 h 
later, AMs were harvested for Western blot. * or ** indicates statistical difference in comparison with CSE-treated group, or CSE-exposed group. (C) Effect 
of simvastatin on binding activity of AP-1 or NF-κB in AMs exposed to CSE. Simvastatin at 10 μM was added 1 h prior to the addition of 2.5% CSE. 24 h 
later, AMs were harvested for a gel shift assay.
al., 2006) or other types of cells (Moodie et al., 
2004). Our present observation concerning late 
ERK activation raises the possibility that CSE may 
activate AMs to release some autocrine factors, 
which may induce MMP-9.
    In this study, we demonstrated inhibitory effect of 
simvastatin on MMP-9 induction using an in vitro 
model. Hence, the present in vitro data may raise 
questions in the context of physiological relevancy. 
However, several reports imply correlation between 
in vitro and in vivo data. Russell et al. (2002) 
reported that CSE treatment for 24 h induced 
higher production of MMP-9 in AMs isolated from 
COPD patients than from normal volunteers or 
healthy smokers. In MonoMac6, a human monocyte- 
macrophage cell line, CSE treatment for 1 h cau-
sed increased IKKα expression, which was also 
observed in AMs in vivo in mouse lungs after 3 
days or 8 weeks of cigarette smoking (Yang et al., 
2008). Moreover, cultured alveolar epithelial cells 
exposed to CSE for 2 h showed increased expre-
ssion in receptor for advanced glycation end-pro-
ducts (RAGE), similar to alveolar/airway epithelial 
cells in lungs of mice exposed to cigarette smoke 
for 6 months (Reynolds et al., 2008). However, 
care must be taken in interpreting or extrapolating 
in vitro data because of in vivo interaction of AMs 
with other types of lung cells or circulatory blood 
cells. Therefore, in vivo experiments are needed to 
confirm whether the beneficial effects of simvas-
tatin may be mediated by inhibition of MMP-9 
induction in AMs.
    Here, we demonstrate that simvastatin can inhibit 
CSE-mediated MMP-9 induction. However, the con-
tribution of MMP-9 in emphysema in COPD has 
been questioned, even with indirect evidence inclu-
ding higher levels of MMP-9 in COPD patients 
(Ohinishi et al., 1998; Russel et al., 2002). Recently, 
converse to this notion, experimentally induced 
adult onset emphysema was reported in MMP-9 
transgenic mice (Foronjy et al., 2008). After 12 
months of age, MMP-9 transgenic mice developed 
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significant air space enlargement together with 
decreased levels of elastin in their alveolar walls. 
In contrast, ablation of the MMP-9 gene did not 
protect mice from the development of emphysema 
induced by repeated intratracheal administration of 
lipopolysaccharide (Brass et al., 2008). Thus, it 
remains debatable whether MMP-9 plays a central 
role in the development of emphysema in COPD. 
However, the contribution of MMP-9 to lung injury 
in the exacerbation phase of COPD cannot be 
excluded, because MMP-9 elevated in the exacer-
bation phase may aggravate inflammation through 
several mechanisms including proteolytic activation 
of pro-inflammatory cytokines such as TNF-α 
(Gearing et al., 1998) and IL-8 (Van den Steen et 
al., 2000).
    In our previous study, we showed that simvas-
tatin attenuates emphysematous change and pul-
monary hypertension, both of which are observed 
in terminal COPD patients (Lee et al., 2005). 
Similar to our previous findings, Takahashi et al. 
(2008) recently reported that simvastatin reverses 
elastase-induced emphysema with alveolar epithe-
lial proliferation, increases VEGF synthesis, and 
elevates eNOS expression. However, whether sim-
vastatin can regenerate damaged lungs in ciga-
rette smoking-induced emphysema remains to be 
demonstrated. This question may be originated 
from RAS potentially mutated by chronic exposure 
to cigarette smoke. In the epithelium of smokers' 
lung, somatic mutations have been identified in 
RAS, p53, EGFR, and PTEN (Anderson and 
Bozinovski, 2003). Until now, these mutations have 
been intensively investigated in the context of 
carcinogenesis. However, evidence is lacking that 
the somatic mutations play a role in persistent 
activation in the context of inflammation and tissue 
remodeling process including MMP-9 induction in 
COPD. In addition, it is unknown whether mutated 
RAS remains as a target of simvastatin in inflam-
matory cells including AMs. These uncertainties 
need to be resolved before any clinical trial of 
simvastatin in human COPD can be undertaken.
Methods
Reagents
Simvastatin, PD98059, U0126, LY294002, SP600125, 
SB203580, geranylgeranyl transferase inhibitor (GGTI), 
farnesyl transferase inhibitor (FTI), BMS- 345541, and IκB 
kinase (IKK) inhibitor VII were purchased from Calbiochem 
(San Diego, CA). GW 5074 was purchased from Tocris 
(Elliville, MI). Dulbecco's DPBS, MEM, and penicillin/ 
streptomycin were obtained from Gibco (Calsbad, CA). 
Geranylgeranyl pyrophosphate (GGPP), farnesyl pyropho-
sphate (FPP), BSA, protease inhibitor cocktail, and gelatin 
were purchased from Sigma-Aldrich (St. Louis, MO). 
Antibodies to p-ERK, p-Akt, Akt, and p-IκB were purchased 
from Cell Signaling Technology (Beverly, MA), and anti-
body to ERK1/2 was obtained from Santa Cruz Biote-
chnology (Santa Cruz, CA). Enhanced chemilumine-
scence detection reagents were purchased from Amer-
sham (Piscataway, NJ).
Isolation and culture of rat AMs
Animal experimentation protocols were approved by the 
Institutional Animal Care and Use Committee of Sung-
kyunkwan University School of Medicine. Male Sprague- 
Dawley rats weighing 250-350 g (Orient, Sungnam, Korea) 
were used for isolation of AMs. After rats were anesthe-
tized by an  intraperitoneal injection of ketamine (90 mg/kg) 
and xylazine (5 mg/kg), the trachea were cannulated and 
AMs were obtained by three bronchoalveolar lavages 
(BALs) using 10 ml of Ca2+- and Mg2+-free DPBS each 
time. Cells recovered from the pooled BAL fluid were 
suspended in MEM containing 0.02% BSA, 25 mM 
HEPES, 100 U/ml of penicillin, and 100 μg/ml of strepto-
mycin. The cells were seeded in either 24-well culture 
plates (Nalge Nunc, Napersville, IL) or 35 mm-diameter 
culture dishes (Nalge Nunc). After incubation for 2 h at 
37oC in a 5% CO2 humidified atmosphere to allow AMs to 
adhere, non-adherent cells were removed by washing one 
time with complete medium. AMs were incubated overnight 
to make them quiescent. Cell viability as determined by 
trypan blue exclusion was ＞ 95% and the purity of AMs as 
determined by nonspecific esterase staining (Sigma- 
Aldrich) was ＞ 90%. AMs from the same rat were used for 
the same series of experiments to reduce inter-individual 
variation.
CSE preparation
CSE was prepared as previously described (Gibbs et al., 
1999) with slight modification. Briefly, mainstream smoke 
from two cigarettes (Eighty Eight Lights, KT&G, Korea) 
yielding 8.5 mg of tar and 0.9 mg of nicotine were 
simultaneously bubbled in 10 ml of MEM containing 25 mM 
HEPES. After determining the absorbance at 340 nm, the 
CSE solution was filtered through a 0.22 μm syringe filter 
(Millipore, Billerica, MA). The filtered CSE solution was 
applied to AMs within 30 min.
Gelatin zymography
Semi-quantitative measurement of MMP-9 activities in 
conditioned media was carried out using zymography 
(Gibbs et al., 1999). After centrifugation of conditioned 
media at 400 g for 5 min, MMP-9 in the conditioned media 
was separated by 8% SDS-PAGE gels containing 2 mg/ml 
porcine skin gelatin. After electrophoresis, the gels were 
washed three times in a washing buffer (20 mM Tris/HCl, 
pH 7.8 and 2.5% Triton X-100) for 15 min at room tem-
perature. The gels were subsequently washed twice for 15 
min in a developing buffer (20 mM Tris/HCl, pH 7.8, 1% 
Triton X-100, 10 mM CaCl2, and 5 μM ZnCl2), incubated for 
18 h at 37oC, stained with 1% Coomassie Blue R-250 in a 
destaining solution containing 40% methanol, 10% acetic 
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acid and 50% water for 20 min, and washed by immersion 
in the destaining solution for 1 h. Gel images were ac-
quired using the LAS 3000 (Fuji, Japan), and analyzed with 
the Image Gauge software (Fuji).
RT-PCR
RT-PCR was performed to analyze mRNA expression of 
MMP-9 and GAPDH. Total RNAs were isolated from atta-
ched AMs using a kit (iNtRON, Sungnam, Korea) accor-
ding to the manufacturer’s instruction. cDNA was synthe-
sized using 0.2 μg total RNAs in 10 μl of Superscript II First 
Strand System reaction mixture (Invitrogen). PCR primers 
used for amplifying MMP-9 and GAPDH were as follows: 
MMP-9, 5'-CAAACCCTGCGTATTTCC-3' and 5'-AGAGTA-
CTGCTTGCCCAGGA-3'; GAPDH gene, 5’-CTCATGACC-
ACAGTCCATGC-3' and 5'-TTCATCGGGATGACCTT-3'). 
PCR was performed with 2 μl of cDNA and 0.2 mM of each 
primer in the Gene Amp PCR system 9700 (Perkin Elmer, 
Norwalk, CT) using touchdown PCR consisting of 2 cycles 
of PCR at 94oC for 1 min, 64oC for 1 min and 72oC for 1 
min, followed by 25 cycles (MMP-9) or 20 cycles (GAPDH) 
of PCR at 94oC for 1 min, 59oC for 1 min and 72oC for 1 
min. The PCR products (MMP-9, 223 bp; GAPDH, 155 bp) 
in 20 μl were resolved by electrophoresis in a 1.5% agarose 
gel containing ethidium bromide. Band intensities were 
quantified by the Gel-Doc system (Kodak, Rochester, NY). 
Western blot analysis
One million AMs were lysed in 100 μl of cold lysis buffer 
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1% Triton X-100, 0.1% SDS, 1% NP-40, 2.5 
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 
mM Na3VO4, 2 mM p-nitrophenyl phosphate, and a pro-
tease inhibitor cocktail). The lysates were centrifuged at 
16,000 g for 20 min at 4oC. Proteins in the supernatant 
were separated by 12% SDS-PAGE and transferred to a 
PVDF membrane (Schleicher & Schuell, Riviera Beach, 
FL). Each membrane was blocked with 5% skim milk in 
T-TBS (Tween 20-Tris buffered saline; 8 g/l NaCl, 0.2 g/l 
KCl, 3 g/l Tris-HCl, pH 7.4, and 0.1% Tween 20) for 1 h at 
room temperature. Then, each membrane was incubated 
overnight at 4oC with a primary antibody at a titer of 
1:1,000. After washing with T-TBS, the membrane was 
incubated with HRP-conjugated secondary antibodies at a 
titer of 1:5,000 for 1 h at room temperature. Proteins were 
visualized using enhanced chemiluminescence reagents 
and LAS-3000.
Determination of RAS activity
RAS activity was assessed using a kit (Upstate Biote-
chnology, Billerica, MA). Briefly, AMs in a 60 mm-diameter 
dish were washed twice with ice-cold PBS and lysed in 200 
μl of MLB buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 
1% lGEPAL CA-630, 10 mM MgCl2, 1 mM EDTA, and 10% 
glycerol) containing a protease inhibitor cocktail and 1 mM 
Na3VO4. After centrifugation at 14,000 g for 10 min, protein 
concentrations were determined using a kit (Bio-Rad, 
Hercules, CA). The cell extract containing 300 μg protein 
was incubated at 4oC for 45 min with 5 μl of agarose slurry 
containing a fusion protein consisting of glutathione S- 
transferase and human RAS-binding domain (residues 
1-149) of RAF1. After the samples were washed three 
times with MLB, activated RAS (RAS-GTP) in the reaction 
mixture was detected by Western blot with anti-RAS 
monoclonal antibody.
Gel shift assay
Nuclear activity of AP-1 or NF-κB was determined with a 
gel shift assay using a kit according to manufacturer's 
instructions (Promega, Madison, WI). In brief, 5'-radio-
labeled AP-1 or NF-κB probe was incubated with 10 μg of 
nuclear proteins at 20oC for 20 min. DNA-protein complex 
was separated in a 4% nondenaturing polyacrylamide gel 
and images were taken with a FLA 3000 phosphoimager 
(Fuji).
Statistical analysis
Data are presented as mean ± SEM of 3 to 6 independent 
experiments. Statistical significance (P ＜ 0.05) was deter-
mined by ANOVA followed by the multiple comparison 
t-test.
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